Get the Stockscreener App
4.33
5.17%
-0.29
Jaguar Health Inc stock is traded at $4.33, with a volume of 83,034.
It is down -5.17% in the last 24 hours and down -64.21% over the past month.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
See More
Previous Close:
$4.62
Open:
$4.62
24h Volume:
83,034
Relative Volume:
0.68
Market Cap:
$5.54M
Revenue:
$10.48M
Net Income/Loss:
$-37.74M
P/E Ratio:
-0.2675
EPS:
-16.1846
Net Cash Flow:
$-29.03M
1W Performance:
-2.42%
1M Performance:
-64.21%
6M Performance:
-83.15%
1Y Performance:
-95.91%
1-Day Range:
$4.26
$4.62
1-Week Range:
$4.26
$4.90
52-Week Range:
$4.02
$110.75
Jaguar Health Inc Stock (JAGX) Company Profile
Name
Jaguar Health Inc
Sector
Industry
Phone
415-371-8300
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
4.36 | 4.61M | 10.48M | -37.74M | -29.03M | -16.18 |
|
ONC
Beone Medicines Ltd Adr
|
245.47 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.48 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.31 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.15 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.62 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Jaguar Health Inc Stock (JAGX) Latest News
Jaguar Health (NASDAQ:JAGX) Upgraded at Wall Street Zen - Defense World
Jaguar Health Filing for Second Indication of Exercise-Induced Diarrhea in Dogs Under MUMS for Crofelemer - ACCESS Newswire
Jaguar Health $1.5M Stock Offering Sparks Retail Buzz; Traders Call It A ‘Dip Opportunity’ - MSN
Jaguar Health Announces $1.5M Direct Stock Offering - TipRanks
Jaguar Health prices 0.25M shares at $6.09 in registered direct offering - MSN
Jaguar Health $1.5M Stock Offering Sparks Retail Buzz; Traders Call It A ‘Dip Opportunity’ By Stocktwits - Investing.com India
Jaguar Health announces $1.5 million direct offering By Investing.com - Investing.com South Africa
Jaguar Health (JAGX) Announces Direct Offering and Private Placement | JAGX Stock News - GuruFocus
Jaguar Health Prices Offering of Shares, Warrants - marketscreener.com
Jaguar Health announces $1.5 million direct offering - Investing.com
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | JAGX Stock News - GuruFocus
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - ACCESS Newswire
Jaguar Health Secures Fresh Capital: $1.5M Direct Offering Plus WarrantsKey Terms Revealed - Stock Titan
SEC Form 424B5 filed by Jaguar Health Inc. - Quantisnow
Jaguar Health (JAGX) Advances Crofelemer Trial for Rare Pediatri - GuruFocus
First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID) | JAGX Sto - GuruFocus
Breakthrough MVID Treatment Reduces Parenteral Support by 27%New Phase 2 Trial Launches for Rare Disease - Stock Titan
Jaguar Health (NASDAQ:JAGX) Now Covered by Analysts at First Berlin - Defense World
JAGX: Jaguar Health Coverage Initiated with Buy Rating | JAGX Stock News - GuruFocus
Jaguar Health outlines rare disease catalyst convergence and expedited regulatory pathways for crofelemer following proof-of-concept results - MSN
Jaguar Health, Inc. (NASDAQ:JAGX) Q1 2025 Earnings Call Transcript - MSN
Jaguar Animal Health: Mixed Sentiments in Latest Earnings Call - TipRanks
Jaguar Health Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Jaguar Health Inc (JAGX) Q1 2025 Earnings Call Highlights: Navigating Challenges with Promising ... - Yahoo Finance
Jaguar Health Inc (JAGX) Q1 2025 Earnings Call Highlights: Navigating Challenges with Promising Clinical Advances - GuruFocus
Jaguar Health Reports Q1 2025 Financial Results - TipRanks
Transcript : Jaguar Health, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
Earnings call transcript: Jaguar Health reports Q1 2025 with stock drop - Investing.com India
Jaguar Animal Health Executes Stock Exchange Agreements - TipRanks
Jaguar Health Reports First Quarter 2025 Financials | JAGX Stock News - GuruFocus
JAGX Reports Decrease in Q1 2025 Product Revenue | JAGX Stock News - GuruFocus
Jaguar Health Reports First Quarter 2025 Financials - ACCESS Newswire
JAGXJaguar Health Inc Latest Stock News & Market Updates - Stock Titan
Jaguar Health, Inc. SEC 10-Q Report - TradingView
JAGX Reports Decrease in Q1 2025 Product Revenue | JAGX Stock Ne - GuruFocus
Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 - GuruFocus
Jaguar Health Earnings Tomorrow: Q1 2025 Results Plus Major Corporate Updates Coming - Stock Titan
Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates - Bellingham Herald
Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates | JAGX Stock News - GuruFocus
Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $5.7 Million - ACCESS Newswire
Jaguar Health Investor Webcast Rescheduled for Wednesday, November 17th at 8:30 AM Eastern Time - ACCESS Newswire
Jaguar Health (JAGX) to Release Quarterly Earnings on Tuesday - Defense World
Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs - The Globe and Mail
Jaguar Health Highlights Promising Crofelemer Study Results - TipRanks
Jaguar Health to Host Investor Webcast Monday, March 14th at 8:30 AM Eastern Time Regarding Q4 2021 Financials & Corporate Updates - ACCESS Newswire
Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, - PharmiWeb.com
Jaguar Health Celebrates National Pet Cancer Awareness Month: Wi - GuruFocus
Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs | JAGX Stock News - GuruFocus
Jaguar Health Inc Stock (JAGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):